Table 1.
Patient characteristics
| Characteristic | ET (n = 139) | pre-PMF (n = 42) | PV (n = 124) | PMF (n = 30) |
|---|---|---|---|---|
| Age, yr | 64 (15–88) | 63 (22–88) | 64.5 (18–91) | 68.0 (40–86) |
| Female:Male | 69:70 | 19:23 | 45:79 | 10:20 |
| Palpable splenomegaly | 0 | 2 (4.8) | 9 (7.3) | 14 (46.7) |
| Laboratory findings | ||||
| WBC, × 109/L | 11.1 ± 4.5 | 14.5 ± 10.4a | 15.3 ± 7.2 | 13.4 ± 11.0 |
| Monocytes, × 109/L | 0.6 ± 0.4 | 0.8 ± 0.4a | 0.7 ± 0.4 | 1.0 ± 0.8 |
| Hemoglobin, g/dL | 13.6 ± 2.2 | 13.0 ± 2.8 | 18.2 ± 2.7 | 10.2 ± 2.5 |
| Platelets, × 109/L | 949.6 ± 385.4 | 1,000.9 ± 746.0a | 510.8 ± 288.1 | 414.7 ± 327.6 |
| LDH, × UNL | 1.1 ± 0.5 | 1.5 ± 0.7a | 1.4 ± 0.5 | 2.1 ± 1.6 |
| Driver gene mutation | ||||
| JAK2V617F | 80/117 (68.4) | 23/32 (71.9) | 104/113 (92.0) | 14/22 (63.6) |
| CALR | 14/117 (12.0) | 4/32 (12.5) | - | 5/22 (22.7) |
| MPL | 0/12 (0.0) | 0/3 (0.0) | - | 0/3 (0.0) |
| JAK2 exon12 | - | - | 5/113 (4.4) | - |
| IPSET | ||||
| Low | 43 (30.9) | - | - | - |
| Intermediate | 42 (30.2) | - | - | - |
| High | 54 (38.8) | - | - | - |
| IPSS | ||||
| Low | - | 23 (54.8) | - | 5 (16.7) |
| Intermediate-1 | - | 15 (35.7) | - | 8 (26.7) |
| Intemediate-2 | - | 3 (7.1) | - | 11 (36.7) |
| High | - | 1 (2.4) | - | 6 (20.0) |
| Comorbidity | ||||
| Hypertension | 50 (36.0) | 21 (50.0) | 73 (58.9) | 10 (33.3) |
| Diabetes mellitus | 19 (13.7) | 9 (21.4) | 30 (24.2) | 7 (23.3) |
| Chronic kidney disease | 21 (15.1) | 9 (21.4) | 29 (23.4) | 3 (10.0) |
| Smoking | 24 (17.3) | 12 (28.6) | 50 (40.3) | 3 (10.0) |
| Treatments | ||||
| Cytoreductive treatment | 104 (74.8) | 32 (83.3) | 107 (86.3) | 16 (53.3) |
| Aspirin | 134 (96.4) | 38 (90.1) | 116 (93.5) | 11 (36.7) |
| FU, mo | 46.1 (0.3–289.3) | 58.1 (0.4–269.5) | 76.6 (0.3–317.9) | 40.2 (0.8–236.8) |
Values are presented as median (range), number (%), or mean ± SD.
ET, essential thrombocythemia; pre-PMF, prefibrotic/early primary myelofibrosis; PV, polycythemia vera; PMF, primary myelofibrosis; WBC, white blood cell; LDH, lactate dehydrogenase; UNL, upper normal limit; JAK2, Janus kinase 2; CALR, calreticulin; MPL, myeloproliferative leukemia; IPSET, International Prognostic Score in Essential Thrombocythemia; IPSS, International Prognostic Scoring System; FU, follow-up.
a
p = 0.05 compared with ET.